GlassScriptPhysician profile
Daniel J Palmieri
NPI 1811172448
$11,524.84
in general payments reported to CMS, 2019-2025
49 companies · $2,877 in 2025
The $2,877 reported for 2025 was more than what 97% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,195 · 2022: $1,866 · 2023: $2,224 · 2024: $2,364 · 2025: $2,877.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,465.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,464.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,607.07 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $1,415.92 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $1,122.94 | 2021-2025 | |
| Lilly USA, LLC | $1,088.55 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $814.91 | 2021-2025 | Evenity, Repatha, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $464.28 | 2021-2025 | |
| Pfizer INC. | $461.34 | 2021-2025 | |
| Abbott Laboratories | $449.95 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Otsuka America Pharmaceutical, INC. | $390.70 | 2021-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $311.84 | 2021-2025 | Trintellix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $306.62 | 2021-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $296.26 | 2021-2024 | Belsomra, Capvaxive, Gardasil |
| Glaxosmithkline, LLC. | $278.62 | 2021-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Lundbeck LLC | $250.61 | 2022-2025 | Rexulti |
| Idorsia Pharmaceuticals US INC | $198.58 | 2022-2024 | Quviviq |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Palmieri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.